Affiliation: Centers for Disease Control and Prevention
- Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007C Vellozzi
Division of HIV AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
J Viral Hepat 18:316-24. 2011..Treatment of HCV infection in patients coinfected with HCV/HIV should be considered a priority, given the increased risk of accelerated end-stage liver disease...
- Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis CK Patel
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
J Viral Hepat 18:331-7. 2011..099). Short-term Rosuvastatin monotherapy is not associated with significant changes in serum or lipid fraction HCV RNA in NR patients. HCV co-localizes with the lowest density lipid fractions in serum...
- Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004Claudia Vellozzi
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Am J Trop Med Hyg 75:333-6. 2006..The use of stress-dose steroids might be a factor that influenced the survival of these YEL-AVD patients and should be further evaluated in the management of both YEL-AVD and wild-type yellow fever septic shock...
- Superinfection following smallpox vaccination (Vaccinia), United States: surveillance January 2003 through January 2004Claudia Vellozzi
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Clin Infect Dis 39:1660-6. 2004..Superinfection is an adverse event following smallpox vaccination. The clinical presentation is similar to that of a large normal vaccine reaction or "robust take," and the frequency is unknown...
- Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010Claudia Vellozzi
Immunization Safety Office, Division of Health Care Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Vaccine 28:7248-55. 2010..Death, Guillain-Barré syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered)...
- Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccineBarbara A Slade
Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop D 26, Atlanta, GA 30333, USA
JAMA 302:750-7. 2009....
- Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoringClaudia Vellozzi
Immunization Safety Office ISO, Office of the Chief Science Officer OCSO, Centers for Disease Control and Prevention, Atlanta, GA, United States
Vaccine 27:2114-20. 2009..No new safety concerns emerged after our review of 15 years of post-licensure surveillance data. These findings provide useful information if pandemic vaccine is rapidly distributed and pre-licensure data are limited...
- The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study)Claudia Vellozzi
Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
Am J Epidemiol 169:642-52. 2009..The SUN Study provides a wealth of data that will inform and improve the clinical management of HIV-infected individuals in the modern era...
- Adverse events associated with smallpox vaccination in the United States, January-October 2003Christine G Casey
Smallpox Vaccine Adverse Event Monitoring and Response Activity, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
JAMA 294:2734-43. 2005....
- Dermatological lesions near the smallpox vaccination site after scab detachmentAndrew Kroger
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Clin Infect Dis 46:S227-33. 2008..Lesions were heterogeneous in morphology, clinical appearance, and histology. The evidence from our case series and follow-up suggests that these lesions are self-limited, without significant clinical sequelae...
- Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003Claudia Vellozzi
Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Clin Infect Dis 41:689-97. 2005..GV may be difficult to distinguish from other rashes, and confirmatory testing is recommended. Careful prevaccination screening probably contributed to the low incidence of these adverse reactions following smallpox vaccination...
- Adequacy of surveillance to detect endemic rubella transmission in the United StatesFrancisco Averhoff
National Center for Preparedness, Detection, and Control of Infectious Diseases proposed, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Clin Infect Dis 43:S151-7. 2006..It is necessary to validate that the observed absence of rubella is due to the disappearance of disease rather than a failure of rubella surveillance...
- Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactionsChristine Casey
Immunization Safety Office, Office of the Chief Science Officer, Office of the Director, Atlanta, GA 30329, USA
MMWR Recomm Rep 55:1-16. 2006..The smallpox vaccine surveillance case definitions presented in the report can be used in future vaccination programs to ensure uniform reporting guidelines and case classification...
- Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the USKate Buchacz
Divisions of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
Antivir Ther 18:65-75. 2013....
- Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommonMartin Steinau
Centers for Disease Control and Prevention, National Center for Zoonotic, Vector Borne and Enteric Diseases, Chronic Viral Diseases Branch Atlanta, GA 30333, USA
J Gen Virol 91:2068-72. 2010..6%) instances (seven anal and two cervical) from eight different participants. Changes in HPV-16 variants in HIV-infected adults were seen most frequently when different anatomical sites were sampled, but were also observed over time...
- Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United StatesL Conley
National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
J Infect Dis 202:1567-76. 2010..The prevalence of and risk factors for abnormal anal cytology among men and women with human immunodeficiency virus (HIV) infection have not been extensively investigated...
- Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003Armenak Asatryan
Science Applications International Corporation and Emory University School of Medicine, Atlanta, GA, USA
Vaccine 26:1166-72. 2008..Thus, HL following MMCV has been reported in the literature and to the VAERS. Further studies are needed to better understand if there is a causal relationship between MMCV and HL...
- Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genesBali Pulendran
Emory Vaccine Center, 954 Gatewood Rd, Atlanta, GA 30329, USA
J Infect Dis 198:500-7. 2008..The mechanisms underlying such events remain a mystery. Here, we present an analysis of the immunologic and genetic factors driving disease in a 64-year-old male who developed viscerotropic symptoms...